Diagnostic Value of 18F labeled PSMA PET/CT Imaging in Biochemical recurrence of Prostate Cancer after Curative Therapy

Background: Prostate cancer is regarded as the second cause of_ cancer-related mortality in males globally. Radiation therapy and/or radical_ prostatectomy are effective forms of treatment. Nevertheless, between 15. and 53% of the treated individuals experienced a biochemical recurrence within ten years.Aim of the Work: To evaluate 18F-PSMA PET/CT imaging's diagnostic efficacy in the biochemical_ prostatic cancer _recurrence after_ radical prostatectomy, hormonal. therapy,_ and radiotherapy.Patients and Methods: The_ study is _conducted in the radiology department at. a tertiary hospital. Twenty-six. patients with treated cancer prostate cancer were referred to. our study who had their PSA levels rising to assess the risk of. local. recurrence.Results: Twenty out of twenty-six patients revealed_ a positive study suggestive of recurrent prostate carcinoma 18F_ PSMA PET/CT with no- definite positive_ scans detected at PSA level > 0.2 ng/ml. Patients were _ divided into. 3 groups according to their PSA level _distribution by the 25th and_ 5th percentiles. Statistically strong _ positive _correlation between_ the PSA level and - number of local or distant recurrences with p-value (_<0.001). However, there was no strong correlation between PSA level and recurrence in osseous regions with p-value (_>0.05).Conclusion: Our results verified the utility of 18F-PSMA-PET/CT in identifying prostatic cancerous biochemical recurrence at various PSA levels. An elevated PSA increases the likelihood of a pathogenic 18F-PSMA PET_CT among patients.